204 related articles for article (PubMed ID: 1457360)
1. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
Blomqvist C; Tiusanen K; Elomaa I; Rissanen P; Hietanen T; Heinonen E; Gröhn P
Br J Cancer; 1992 Dec; 66(6):1171-6. PubMed ID: 1457360
[TBL] [Abstract][Full Text] [Related]
2. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
Rivera E; Holmes FA; Buzdar AU; Asmar L; Kau SW; Fraschini G; Walters R; Theriault RL; Hortobagyi GN
Breast J; 2002; 8(1):2-9. PubMed ID: 11856154
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
5. The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial.
Saarto T; Blomqvist C; Tiusanen K; Gröhn P; Rissanen P; Elomaa I
Eur J Surg Oncol; 1995 Apr; 21(2):146-50. PubMed ID: 7720887
[TBL] [Abstract][Full Text] [Related]
6. Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen.
Arriagada R; Spielmann M; Koscielny S; Le Chevalier T; Delozier T; Ducourtieux M; Tursz T; Hill C
Ann Oncol; 2002 Sep; 13(9):1378-86. PubMed ID: 12196363
[TBL] [Abstract][Full Text] [Related]
7. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
Fukuda M; Yamaguchi S; Ohta T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):77-81. PubMed ID: 10442369
[TBL] [Abstract][Full Text] [Related]
10. Local-regional recurrence in breast cancer after mastectomy and adriamycin-based adjuvant chemotherapy: evaluation of the role of postoperative radiotherapy.
Sykes HF; Sim DA; Wong CJ; Cassady JR; Salmon SE
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):641-7. PubMed ID: 2921164
[TBL] [Abstract][Full Text] [Related]
11. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
12. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.
Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Askergren J; Friberg S
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):629-39. PubMed ID: 2493433
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404.
Shien T; Iwata H; Fukutomi T; Inoue K; Aogi K; Kinoshita T; Ando J; Takashima S; Nakamura K; Shibata T; Fukuda H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):603-9. PubMed ID: 25055938
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
18. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group.
Olson JE; Neuberg D; Pandya KJ; Richter MP; Solin LJ; Gilchrist KW; Tormey DC; Veeder M; Falkson G
Cancer; 1997 Mar; 79(6):1138-49. PubMed ID: 9070491
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast.
Kimmick GG; Shelton BJ; Case LD; Cooper MR; Muss HB
Breast Cancer Res Treat; 2002 Apr; 72(3):233-43. PubMed ID: 12058965
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
